Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.

Allergologia et immunopathologia - 1 Jan 2026

Tuğlu Hatice Çelik, Aksu Kurtuluş, Akkale Özgür, Telli Onur, Çelik Fatma Dindar, Yağdıran Melis, Göktürk Özge, Solak Gürgün Tuğe Vural, Aksu Funda

Abstract excerpt

INTRODUCTION: Identifying the eosinophilic, neutrophilic, or infectious phenotypes of exacerbations, particularly those occurring during biologic agent therapy, may provide valuable guidance for determining maintenance therapy for patients and preventing recurrent exacerbations. Our study primarily aimed to evaluate the clinical phenotypic features of exacerbations in patients with severe asthma receiving...

Topics

Join the communities discussing this publication.

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Asthma
C-Reactive Protein
Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Leukocyte Count

Severity of Illness Index

Source

Identifiers

PMID: 41814604
DOI: 10.15586/aei.v54i2.1545

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.PMID 41814604Read ↗

Acute asthma exacerbations: phenotypes and management.Semantic proximity Read ↗

Clinical characteristics of eosinophilic asthma exacerbations.Semantic proximity Read ↗

Biomarker defined infective and inflammatory asthma exacerbation phenotypes in hospitalized adults: clinical impact and phenotype stability at recurrent exacerbation.Semantic proximity Read ↗

The Role of Inflammatory Phenotype in Patients With Exacerbation-prone Asthma and Ongoing Therapy.Semantic proximity Read ↗

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils.Semantic proximity Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Exacerbations of severe asthma.Semantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.